Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RNAC · as of Sep 30, 2025
Ownership Breakdown
70
Institutional Holders
▲ 2 vs Q2
$60.90M
Total Inst. Value
▼ $5.57M vs Q2
29.38M
Shares Outstanding
freeFloat 36.18%
5.97M
13F Shares Held
▼ 432,849 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RNAC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 2.16M | 8.30% | 8.30% | $22.03B | Nov 13, 2025 | ▼ 178.3K |
BLACKROCK, INC. pharmaceutical preparations | 649.3K | 2.50% | 2.50% | $6.64B | Nov 12, 2025 | ▼ 4.5K |
SIREN, L.L.C. pharmaceutical preparations | 563.3K | 2.17% | 2.17% | $5.76B | Nov 13, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 520.7K | 2.00% | 2.00% | $5.32B | Nov 7, 2025 | ▲ 24.4K |
BIOIMPACT CAPITAL LLC pharmaceutical preparations | 380.0K | 1.46% | 1.46% | $3.88B | Nov 14, 2025 | ▼ 306.0K |
ERSTE ASSET MANAGEMENT GMBH pharmaceutical preparations | 260.0K | 1.00% | 1.00% | $2.56B | Nov 12, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 241.8K | 93.08% | 93.08% | $2.47B | Nov 12, 2025 | ▲ 22.9K |
683 CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 230.0K | 88.53% | 88.53% | $2.35B | Nov 14, 2025 | ▲ 11.0K |
STATE STREET CORP pharmaceutical preparations | 197.7K | 76.08% | 76.08% | $2.02B | Nov 14, 2025 | ▲ 3.4K |
NORTHERN TRUST CORP pharmaceutical preparations | 91.3K | 35.14% | 35.14% | $932.97M | Nov 14, 2025 | ▲ 8.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+169.0K shares3
New Positions
first time holders15
Decreased
−583.9K shares0
Sold Out
fully exitedNet shares change (top 50)
414.9K
+169.0K / −583.9K
Net new holders
+9
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RNAC insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
24
Buy transactions
4
Sell transactions
6.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Singer Michael director | Mar 13, 2026 | Gift | 6,555 | — | — | 49.6K | Form 4 ↗ |
Brunn Carsten President and CEO | Jan 6, 2026 | Sale | 23,766 | $6.82 | $162.1K | 323.5K | Form 4 ↗ |
Miljkovic Milos Chief Medical Officer | Jan 6, 2026 | Sale | 3,573 | $6.82 | $24.4K | 58.8K | Form 4 ↗ |
Davis Blaine Chief Financial Officer | Jan 6, 2026 | Sale | 10,591 | $6.82 | $72.2K | 121.2K | Form 4 ↗ |
DeSilva Nishan M director | Jan 2, 2026 | Award | 2,600 | — | — | 11.4K | Form 4 ↗ |
DeSilva Nishan M director | Jan 2, 2026 | Award | 7,800 | $6.76 | $52.7K | 7.8K | Form 4 ↗ |
Brunn Carsten President and CEO | Jan 2, 2026 | Award | 415,700 | $6.76 | $2.81M | 415.7K | Form 4 ↗ |
Brunn Carsten President and CEO | Jan 2, 2026 | Award | 143,200 | — | — | 347.3K | Form 4 ↗ |
Malik Kemal director | Jan 2, 2026 | Award | 2,600 | — | — | 11.1K | Form 4 ↗ |
Malik Kemal director | Jan 2, 2026 | Award | 7,800 | $6.76 | $52.7K | 7.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cartesian Therapeutics, Inc. (RNAC) is primarily owned by institutional investors, who hold approximately 20.3% of total shares outstanding. Company insiders own approximately 63.82%, while retail and public investors account for the remaining 15.87%.
The largest institutional shareholder of Cartesian Therapeutics, Inc. is FMR LLC, holding approximately 2.16 million shares — equal to 8.30% of outstanding shares — as of September 30, 2025.
A total of 70 institutional investors currently hold RNAC stock, with a combined institutional value of approximately $60,899,005 as of the most recent 13F filing period.
Frequently asked questions
RNAC ownershipCartesian Therapeutics, Inc. (RNAC) is primarily owned by institutional investors, who hold approximately 20.3% of shares. The largest shareholder is FMR LLC with a 8.30% stake. Company insiders hold 63.82%. Data sourced from SEC Form 13F as of September 30, 2025.